Orthocell well positioned to capitalise on its expanded access

Orthocell is leading regenerative medicine with proprietary collagen devices which targets bone, nerve and tendon repair gaps. Aging populations, trauma care needs and medtech-energy synergies position it for global scale and shareholder value via operational excellence and pipeline growth.

Orthocell Limited (ASX: OCC) 

is showing a strong momentum in the regenerative medicine sector which is highlighted by recent US Department of Defense (DoD) and Veterans Affairs (VA) approvals for its flagship Remplir nerve repair device. This milestone was announced on 15 April 2026 and it unlocks access to 51 military hospitals and 170 VA medical centers amplifying its US commercialization efforts amid steady revenue growth and expanding global approvals.

Strong Market Momentum

Orthocell has built significant traction since Remplir's US launch in June 2025 with unit sales surging to 110-120 in Q3 FY26 which is a remarkable 380% compound quarterly growth rate (CQGR).

Cumulative figures show 52 hospitals (273% CQGR) and 48 surgeons (263% CQGR) supported by 32 Value Analysis Committee (VAC) approvals covering over 115 facilities and 57 more pending. In Australia and New Zealand (AUNZ), Remplir has achieved nearly 100% year-over-year sales growth engaging 314 surgeons across 224 hospitals and nearing 5,500 cumulative units sold.

This performance underscores investor optimism in Orthocell's collagen-based platform which targets the underserved $1.6 billion US peripheral nerve repair market where devices penetrate only 10% of 700,000+ annual procedures dominated by suboptimal suturing (50-70% success rates). 

Remplir's advantages, including its natural epineurium-mimicking design, ease of suturing and scar protection position it for broader adoption and it is further validated by real-world use in Ukraine's conflict injuries.

Impressive Financials and Operational Progress

Revenue has maintained consistent upward trajectory over the last three half-years (21% compound semi-annual growth rate) fueled primarily by device sales from Remplir, Striate and emerging SmrtGraft for tendon repair. Orthocell remains fully funded with $49.4 million in cash reserves (including term deposits) providing a runway above the high $20 millions to reach cash breakeven at just 5,000-6,000 US procedures annually. This is equivalent to under 1% market share via 300-400 active surgeons already in its VAC pipeline. 

Manufacturing upgrades including a $5.5 million Stage 1 expansion for fourfold capacity increase and automation will cut unit costs and enable 24 hour operations by late 2027 without added headcount. These efficiencies paired with a lean US team signal disciplined scaling toward profit.

Strategic Diversification and Long-Term Catalysts

Orthocell is diversifying applications beyond core nerve repair, notably Remplir's promising off-label use in prostate cancer surgery to preserve neurovascular bundles, potentially mitigating 80% erectile dysfunction and 35% incontinence rates post-procedure. Initial Australian data from almost 200 cases is slated for 2H CY26 which could vastly expand the total addressable market. 

The pipeline extends to autologous cell therapies for tendon and cartilage regeneration with US FDA engagement underway for faster market entry. Near-term catalysts include first Canada sales and exclusive distributor appointments in 1H CY26, EU/UK clearances in 2H CY26 and Asia expansion (Hong Kong live, Thailand/Canada approved).

With products cleared in nine jurisdictions, in-house IP/manufacturing and a three-year vision targeting ASX 300 status through Americas dominance, ANZ/Asia growth, and organizational excellence, Orthocell is primed for sustained value creation. Its strong balance sheet supports this trajectory, offering potential for attractive returns in a high-growth medtech niche.

(Source: Company Announcements)